Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Abstract

Mepacrine inhibits matrix metalloproteinases-1 (MMP-1) and MMP-9 activation in human fibroblast-like synoviocytes.

Karl M Stuhlmeier
The Journal of Rheumatology November 2003, 30 (11) 2330-2337;
Karl M Stuhlmeier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

OBJECTIVE: Matrix metalloproteinases (MMP) are enzymes known to be involved in normal physiological and in many pathological conditions. Rheumatic diseases are among the ailments where MMP have been shown to exert detrimental effects. Mepacrine is used alone or in combination with other drugs to treat lupus and other rheumatic diseases. We investigated whether mepacrine's beneficial effects might be due to its influence on MMP. METHODS: Human fibroblast-like synoviocytes were used to study the effect of mepacrine on phorbol myristic acetate (PMA) induced activation of MMP. Western blot, reverse transcription-polymerase chain reaction, and electrophoretic mobility shift assay (EMSA) experiments were used to investigate the effect of mepacrine. RESULTS: Mepacrine selectively inhibited MMP in human fibroblast-like synoviocytes. Mepacrine inhibited MMP-1 as well as MMP-9, but had no effect on MMP-3 at the mRNA level. Possible mechanisms to explain these findings were investigated, and it was found that mepacrine had a strikingly different effect on c-Jun, as opposed to c-Fos activation. While mepacrine treatment alone led to increased concentrations of c-Jun within the nuclear compartment, c-Fos translocation into the nucleus was blocked in synoviocytes treated with mepacrine and stimulated with PMA. Accordingly, EMSA showed reduced AP-1 binding in mepacrine treated synoviocytes. These results imply that the observed effects of mepacrine on immediate early genes resulted in reduced AP-1 binding. That ultimately led to a selective suppression of genes that rely on unhindered assembling of these transcription factors for their activation. CONCLUSION: Selective inhibition of MMP by mepacrine might in part explain the beneficial effects of this drug in the treatment of certain diseases.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 30, Issue 11
1 Nov 2003
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Mepacrine inhibits matrix metalloproteinases-1 (MMP-1) and MMP-9 activation in human fibroblast-like synoviocytes.
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Mepacrine inhibits matrix metalloproteinases-1 (MMP-1) and MMP-9 activation in human fibroblast-like synoviocytes.
Karl M Stuhlmeier
The Journal of Rheumatology Nov 2003, 30 (11) 2330-2337;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Mepacrine inhibits matrix metalloproteinases-1 (MMP-1) and MMP-9 activation in human fibroblast-like synoviocytes.
Karl M Stuhlmeier
The Journal of Rheumatology Nov 2003, 30 (11) 2330-2337;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire